GAMMA-GLUTAMYL-TRANSFERASE TRANSPEPTIDASE IN THE PROGNOSIS OF PATIENTS WITH UVEAL MALIGNANT-MELANOMA
GAMMA-GLUTAMYL-TRANSFERASE TRANSPEPTIDASE IN THE PROGNOSIS OF PATIENTS WITH UVEAL MALIGNANT-MELANOMA
复制标题
DOI：
10.1016/0002-9394(83)90266-0
复制
发表时间：
1983-01-01
影响因子：
4.2
通讯作者：
AMSEL, J
中科院分区：
文献类型：
--
作者：
FELBERG, NT;SHIELDS, JA;AMSEL, J
一项对116例经组织学证实的葡萄膜恶性黑色素瘤患者的研究表明，在15例（13%）患者通过血清γ诊断出眼部肿瘤的同时，肝转移也存在。-谷氨酰转肽酶测定。治疗前的平均。-谷氨酰转肽酶水平在28例发生转移的患者中比在88例临床无转移的患者随访至少2年的患者中有统计学差异（P < 0.01）。-谷氨酰转肽酶水平。在发生转移的患者中升高22 IU/ml。在这个正常上限下，28名后来出现临床转移证据的患者中有15名（54%）在治疗前水平升高。相比之下，88例至少2年无肿瘤的患者中只有12例（14%）的治疗前水平升高。虽然并非所有发生转移的患者在治疗前水平都有所增加，但大多数患者在其疾病过程中的某个时间出现了增加。因为。-谷氨酰转肽酶检测可以在其他肝功能检测之前发现肝转移，应作为葡萄膜恶性黑色素瘤患者的常规肝功能研究。
A study of 116 patients with histologically proven uveal malignant melanoma suggested that hepatic metastases were present at the same time that the ocular tumor was diagnosed in 15 patients (13%) by serum .gamma.-glutamyl transpeptidase assay. The average pretherapy .gamma.-glutamyl transpeptidase levels were statistically higher (P < 0.01) in the 28 patients who developed metastases compared with those in 88 patients who have remained clinically free of metastases for a follow-up period of at least 2 yr. The predictive value test indicated that pretherapy .gamma.-glutamyl transpeptidase levels .gtoreq. 22 IU/ml were increased in patients developing metastasis. With this upper-normal limit, 15 (54%) of the 28 patients who later developed clinical evidence of metastasis had increased pretherapy levels. In comparison, only 12 (14%) of the 88 patients who remained tumor-free for at least 2 yr had increased pretherapy levels. Although not all patients who developed metastases had increased pretherapy levels, most developed increases at some time during the course of their disease. Because the .gamma.-glutamyl transpeptidase assay can detect hepatic metastases before other liver function assays, it should be included as a routine liver function study for patients with uveal malignant melanoma.